The long term goal of this research is to reduce or eliminate blindness due to diseases of the back of the eye by developing sustained release intravitreal injectable formulations for anti-inflammatory drugs. We hope that these formulations will allow less frequent dosing than is achievable with current formulations, such as triamcinolone and reduce the incidence of steroid glaucoma.